Lars Bastholt
Experienced in Metastatic Brain Tumor

Lars Bastholt

Sdr. Boulevard 29, 
Odense C, DK 
Experienced in Metastatic Brain Tumor
Sdr. Boulevard 29, 
Odense C, DK 
OverviewLocationsClinical Research

Overview

Lars Bastholt practices in Odense C, Denmark. Mr. Bastholt is rated as an Experienced expert by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Melanoma, Thyroid Cancer, Metastatic Uveal Melanoma, Medullary Thyroid Carcinoma, and Thyroidectomy.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Metastatic Brain Tumor.

Gender
Male

Locations

Sdr. Boulevard 29, Odense C, 5000, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Enrollment Status: Unknown
Publish Date: March 04, 2019
Intervention Type: Biological
Study Drug: PEG IFN Alfa-2b
Study Phase: Phase 3

116 Total Publications

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.
Journal: Journal of the National Cancer Institute
Published: June 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bastholt's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile